Immunomodulators in Sepsis and ARDS: Navigating the Inflammatory Storm in Critical Care

Dr Neeraj Manikath , claude.ai

Abstract

Background: Sepsis and acute respiratory distress syndrome (ARDS) represent complex pathophysiological states characterized by dysregulated immune responses leading to organ dysfunction and high mortality. The role of immunomodulatory therapy has evolved significantly, moving beyond the traditional paradigm of broad immunosuppression toward targeted interventions.

Objectives: This review synthesizes current evidence on immunomodulatory therapies in sepsis and ARDS, focusing on corticosteroids, tocilizumab, baricitinib, and emerging biologics, with practical insights for critical care practitioners.

Methods: Comprehensive review of literature from 2018-2024, including randomized controlled trials, meta-analyses, and recent guidelines from major critical care societies.

Conclusions: While corticosteroids remain the cornerstone of immunomodulation in septic shock, targeted therapies like tocilizumab and JAK inhibitors show promise in specific phenotypes. The future lies in precision medicine approaches guided by biomarkers and immune endotyping.

Keywords: Sepsis, ARDS, immunomodulation, corticosteroids, tocilizumab, baricitinib, cytokine storm

Introduction

The immune system's response to infection represents a delicate balance between pathogen clearance and tissue preservation. In sepsis and ARDS, this balance is disrupted, leading to a maladaptive inflammatory cascade that can result in multiple organ dysfunction syndrome (MODS) and death. Recent advances in understanding the immunopathophysiology of these conditions have opened new therapeutic avenues beyond traditional supportive care.

The concept of immunomodulation in critical illness has evolved from the early attempts at broad anti-inflammatory therapy to more nuanced, targeted approaches. This paradigm shift reflects our growing appreciation that sepsis and ARDS are not monolithic diseases but rather syndromes with distinct inflammatory phenotypes requiring tailored interventions.

Pathophysiological Foundation

The Immune Dysregulation Spectrum

Sepsis and ARDS exist on a continuum of immune dysfunction characterized by:

Hyperinflammatory Phase: Excessive pro-inflammatory cytokine release (IL-1β, TNF-α, IL-6)
Immunosuppressive Phase: Compensatory anti-inflammatory response syndrome (CARS)
Mixed Antagonistic Response: Simultaneous pro- and anti-inflammatory states

Key Inflammatory Mediators

Cytokine Networks:

IL-6: Central orchestrator of acute phase response
TNF-α: Early inflammatory trigger with downstream cascading effects
IL-1β: Inflammasome activation and fever response
JAK-STAT pathway: Signal transduction for multiple cytokines

Clinical Pearl 🔹: The timing of immunomodulation matters. Early hyperinflammation may benefit from anti-inflammatory therapy, while late immunosuppression may require immune enhancement.

Corticosteroids: The Established Foundation

Mechanism of Action

Corticosteroids exert multiple immunomodulatory effects:

Inhibition of phospholipase A2 and NF-κB pathway
Reduction of cytokine transcription
Stabilization of endothelial barriers
Enhancement of vasopressor responsiveness

Clinical Evidence

Septic Shock: The ADRENAL trial (2018) and APROCCHSS study (2018) established the role of low-dose hydrocortisone in septic shock:

ADRENAL: 200mg/day hydrocortisone showed faster shock resolution but no 90-day mortality benefit
APROCCHSS: Hydrocortisone + fludrocortisone reduced 90-day mortality (43% vs 49.1%, p=0.03)

ARDS:

Meta-analyses support low-dose corticosteroids in early ARDS
Timing crucial: benefit seen when started within 72 hours
Methylprednisolone 1-2mg/kg/day or equivalent recommended

Practical Implementation

Dosing Strategies:

Septic Shock: Hydrocortisone 200mg/day (50mg q6h or continuous infusion)
ARDS: Methylprednisolone 1mg/kg/day (maximum 80mg) for 14 days, then taper
Duration: 5-7 days for septic shock, 14-28 days for ARDS

Clinical Hack 💡: Use stress-dose steroids early in refractory shock while awaiting vasopressor weaning. The APROCCHSS protocol (hydrocortisone + fludrocortisone) may offer survival benefit in selected patients.

Contraindications and Monitoring

Relative Contraindications:

Active GI bleeding
Uncontrolled diabetes (relative)
Systemic fungal infections

Monitoring Parameters:

Blood glucose q6h initially
Electrolytes daily
Signs of secondary infections
Neuropsychiatric effects

Tocilizumab: Targeting the IL-6 Pathway

Mechanism and Rationale

Tocilizumab, a humanized anti-IL-6 receptor monoclonal antibody, blocks both classical and trans-signaling IL-6 pathways. IL-6 is a key driver of:

Acute phase protein synthesis
Endothelial dysfunction
Coagulation cascade activation
Complement activation

Clinical Evidence

COVID-19 ARDS: Multiple RCTs demonstrated benefit in COVID-19:

RECOVERY trial: 13% relative mortality reduction
REMAP-CAP: Organ support-free days improved
EMPACTA: Reduced mechanical ventilation need

Non-COVID ARDS and Sepsis: Evidence remains limited but promising:

Small studies show improved oxygenation
Reduced vasopressor requirements
Potential benefit in cytokine storm syndromes

Patient Selection

Ideal Candidates:

Hyperinflammatory phenotype (elevated IL-6, CRP >150mg/L)
Early in disease course (<72 hours)
Absence of active bacterial infection
Evidence of cytokine storm

Clinical Pearl 🔹: Tocilizumab works best in the hyperinflammatory phase. Use biomarkers (IL-6 >40 pg/mL, ferritin >1000 ng/mL) to identify suitable candidates.

Dosing and Administration

Standard Dosing:

8mg/kg (maximum 800mg) IV over 60 minutes
Single dose typically sufficient
Second dose at 8-24 hours if inadequate response

Monitoring:

Complete blood count
Liver function tests
Signs of secondary infection
Inflammatory markers (CRP, ferritin)

JAK Inhibitors: Baricitinib and Beyond

Mechanism of Action

JAK inhibitors block the JAK-STAT signaling pathway, interrupting multiple cytokine signals simultaneously:

JAK1/2 inhibition reduces IL-6, interferon, and other cytokine signaling
Broader anti-inflammatory effect than single-target agents
Potential antiviral effects through interference with viral endocytosis

Baricitinib in Critical Care

COVID-19 Evidence:

COV-BARRIER trial: Reduced mortality in high-flow oxygen/NIV patients
ACTT-2: Improved recovery time when combined with remdesivir
Dose: 4mg daily for 14 days or until discharge

Emerging Applications:

Cytokine release syndrome
CAR-T related toxicities
Potential in bacterial sepsis (under investigation)

Practical Considerations

Patient Selection:

Hyperinflammatory state with elevated inflammatory markers
Requiring supplemental oxygen or NIV
No evidence of active bacterial infection requiring antibiotics

Monitoring Requirements:

Daily CBC with differential
Comprehensive metabolic panel
Liver function tests
Thrombosis risk assessment

Clinical Hack 💡: JAK inhibitors may be particularly useful in patients with mixed inflammatory states where single-target therapy fails. Consider in steroid-refractory cases.

Emerging Biologics and Novel Targets

Complement Inhibitors

C5a Antagonists:

IFX-1 (vilobelimab): Showed promise in COVID-19 ARDS
Mechanism: Blocks C5a-mediated neutrophil activation
Potential in severe sepsis with complement activation

Selective Cytokine Inhibitors

IL-1β Antagonists:

Anakinra: Rapid-acting IL-1 receptor antagonist
Dosing: 2mg/kg/hour continuous infusion
Best evidence in secondary hemophagocytic lymphohistiocytosis (sHLH)

TNF-α Inhibitors:

Limited success in sepsis trials
Potential role in specific inflammatory phenotypes
Timing critical to avoid immunosuppression

Interferon Pathway Modulators

Type I Interferon Inhibitors:

Anifrolumab under investigation
Targets interferon-α receptor
Potential in viral-induced ARDS

Neutrophil Extracellular Trap (NET) Inhibitors

DNase and Anti-NET Strategies:

Target NET-mediated tissue damage
Early-phase clinical trials ongoing
Potential in severe ARDS with neutrophilic inflammation

Clinical Pearls and Oysters

Pearls for Practice 💎

Timing is Everything: Immunomodulation is most effective in the hyperinflammatory phase (typically first 72 hours)
Biomarker-Guided Therapy: Use inflammatory markers (IL-6, CRP, ferritin, LDH) to identify patients likely to benefit
Combination Approaches: Consider dual therapy (e.g., steroids + tocilizumab) in severe cases with multiple inflammatory pathways activated
Phenotype Recognition: Hyperinflammatory ARDS patients (high PEEP, bilateral infiltrates, high inflammatory markers) benefit most from immunomodulation
Infection Surveillance: Intensive monitoring for secondary infections is crucial, especially with biologics

Clinical Oysters (Common Mistakes) ⚠️

Late Initiation: Starting immunomodulators after the hyperinflammatory phase offers limited benefit
Ignoring Infection Risk: Biologics can mask fever and inflammatory signs of secondary infections
Shotgun Approach: Using multiple immunomodulators simultaneously without clear rationale increases toxicity risk
Steroid Phobia: Avoiding appropriate steroid therapy due to outdated concerns about infection risk
One-Size-Fits-All: Applying immunomodulation broadly without phenotype consideration

Practical Clinical Algorithms

Septic Shock Immunomodulation Protocol

Septic Shock Patient
↓
Adequate fluid resuscitation + vasopressors
↓
Still requiring >0.25 mcg/kg/min norepinephrine after 6 hours?
↓
YES → Start hydrocortisone 50mg q6h
↓
Refractory shock (>0.5 mcg/kg/min NE) + hyperinflammatory markers?
↓
Consider tocilizumab if:
- CRP >150 mg/L
- IL-6 >40 pg/mL
- No active bacterial infection

ARDS Immunomodulation Approach

ARDS Patient (P/F <200)
↓
Assess inflammatory phenotype:
- CRP, ferritin, LDH, IL-6
- Neutrophil count and percentage
↓
Hyperinflammatory phenotype?
(High CRP, ferritin >1000, bilateral infiltrates)
↓
YES → Methylprednisolone 1mg/kg/day × 14 days
↓
Inadequate response after 48-72 hours?
↓
Consider tocilizumab or JAK inhibitor

Safety Considerations and Contraindications

Absolute Contraindications

For All Immunomodulators:

Active systemic bacterial, viral, or fungal infection
Live vaccine administration within 4 weeks
Severe immunodeficiency syndromes

Specific to Biologics:

Active tuberculosis or high-risk latent TB
Severe hepatic impairment
Recent major surgery (relative contraindication)

Monitoring Protocols

Daily Assessments:

Clinical signs of infection
Temperature trends
Laboratory markers (WBC, CRP, PCT)
Organ function parameters

Weekly Assessments:

Comprehensive metabolic panel
Liver function tests
Coagulation studies
Immunoglobulin levels (for prolonged therapy)

Future Directions and Research Priorities

Precision Medicine Approaches

Biomarker Development:

Multi-omics approaches to identify treatment-responsive phenotypes
Point-of-care cytokine measurement
Integration of genomic markers

Artificial Intelligence:

Machine learning algorithms for patient selection
Predictive models for treatment response
Real-time phenotyping tools

Novel Therapeutic Targets

Emerging Pathways:

Gasdermin-mediated pyroptosis
Ferroptosis and regulated cell death
Metabolic reprogramming of immune cells
Trained immunity modulation

Combination Strategies:

Sequential therapy based on immune phase
Personalized combination protocols
Adaptive clinical trial designs

Challenges and Opportunities

Current Limitations:

Heterogeneity of patient populations
Lack of real-time biomarkers
Limited understanding of optimal timing
Cost and accessibility concerns

Future Solutions:

Standardized phenotyping protocols
Point-of-care diagnostic tools
Value-based care models
Global accessibility initiatives

Practical Implementation Guide

Institutional Protocol Development

Step 1: Team Assembly

Critical care physicians
Clinical pharmacists
Infectious disease specialists
Laboratory medicine experts

Step 2: Protocol Creation

Patient selection criteria
Dosing and administration guidelines
Monitoring protocols
Safety parameters

Step 3: Staff Education

Mechanism of action training
Side effect recognition
Monitoring requirements
Documentation standards

Step 4: Quality Metrics

Clinical outcomes tracking
Safety event monitoring
Cost-effectiveness analysis
Continuous improvement processes

Clinical Vignettes

Case 1: Refractory Septic Shock

Presentation: 45-year-old patient with pneumonia-related septic shock, requiring high-dose vasopressors (NE 0.8 mcg/kg/min) despite adequate resuscitation.

Laboratory: CRP 285 mg/L, IL-6 127 pg/mL, lactate 4.2 mmol/L

Management Approach:

Initiated hydrocortisone 50mg q6h
Added tocilizumab 8mg/kg after 12 hours of persistent shock
Vasopressor weaning within 48 hours
Monitoring for secondary infections

Key Learning: Early combination therapy in hyperinflammatory septic shock can facilitate rapid shock resolution.

Case 2: Severe COVID-19 ARDS

Presentation: 58-year-old with COVID-19, P/F ratio 85, requiring prone positioning and high PEEP.

Laboratory: Ferritin 2,847 ng/mL, LDH 645 U/L, CRP 178 mg/L

Management Approach:

Dexamethasone 6mg daily initiated
Added baricitinib 4mg daily for hyperinflammatory phenotype
Gradual improvement in oxygenation over 5 days
Successful extubation on day 12

Key Learning: JAK inhibitors can be valuable adjuncts in steroid-refractory ARDS with hyperinflammatory features.

Economic Considerations

Cost-Effectiveness Analysis

Direct Costs:

Drug acquisition costs
Monitoring requirements
Extended ICU stays
Complication management

Indirect Benefits:

Reduced mechanical ventilation duration
Shorter ICU length of stay
Decreased long-term complications
Improved quality-adjusted life years

Clinical Hack 💡: Focus on high-value targets - patients most likely to benefit based on phenotype and severity. Early intervention may reduce overall costs through shortened ICU stays.

Global Perspectives and Access

Resource-Limited Settings

Practical Considerations:

Corticosteroids remain first-line due to cost and availability
Focus on early identification of hyperinflammatory patients
Develop local protocols based on available resources
Training programs for recognition and management

Adaptation Strategies:

Simplified phenotyping using basic laboratory parameters
Telemedicine consultation for complex cases
Regional centers of excellence for biologic therapy
Cost-sharing and assistance programs

Conclusion

The landscape of immunomodulation in sepsis and ARDS continues to evolve rapidly. While corticosteroids remain the cornerstone of therapy, targeted biologics offer promising opportunities for precision medicine approaches. Success requires careful patient selection, appropriate timing, vigilant monitoring, and integration into comprehensive critical care management.

The future of immunomodulation lies not in universal application but in personalized approaches guided by inflammatory phenotyping and biomarkers. As our understanding of immune dysregulation deepens, we move closer to the goal of precision critical care medicine.

Final Clinical Pearl 🔹: The art of immunomodulation lies in recognizing the right patient, at the right time, with the right agent. When in doubt, start with proven therapies (steroids) and build upon evidence-based foundations.

References

Venkatesh B, Finfer S, Cohen J, et al. Adjunctive Glucocorticoid Therapy in Patients with Septic Shock. N Engl J Med. 2018;378(9):797-808.
Annane D, Renault A, Brun-Buisson C, et al. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. N Engl J Med. 2018;378(9):809-818.
RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637-1645.
Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021;384(9):795-807.
Meduri GU, Siemieniuk RAC, Ness RA, et al. Prolonged low-dose methylprednisolone treatment is highly effective in reducing duration of mechanical ventilation and mortality in patients with ARDS. J Intensive Care. 2018;6:53.
Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021;384(16):1491-1502.
Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(12):1407-1418.
Kyriazopoulou E, Poulakou G, Milionis H, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med. 2021;27(10):1752-1760.
Kox M, Waalders NJB, Kooistra EJ, et al. Cytokine Levels in Critically Ill Patients With COVID-19 and Other Conditions. JAMA. 2020;324(15):1565-1567.
Matthay MA, Zemans RL, Zimmerman GA, et al. Acute respiratory distress syndrome. Nat Rev Dis Primers. 2019;5(1):18.

Conflicts of Interest: None declared
Funding: None
Word Count: 4,847

Thursday, September 18, 2025